Abbott Sells In Vitro, Point-Of-Care Diagnostics Businesses To General Electric For $8 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal continues Abbott’s strategy over the last few years of becoming more focused on its pharmaceuticals business.
You may also be interested in...
Abbott Finds Lipid Lowering Partner With Kos Acquisition
Candidates would be competitors to Pfizer's Lipitor/torcetrapib combination.
Hospira Spins Off With $4.2 Bil. Market Cap; Abbokinase Stays With Abbott
Abbott initially pegged Abbokinase as one of its hospital-based products to be divested with Hospira, but later decided the drug had a more strategic fit with the rest of its Rx portfolio.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.